SMAD2/3 Mediate Oncogenic Effects of TGF-β in the Absence of SMAD4

Scientists provided evidence of a SMAD2/3 oncogenic effect in response to TGF-β1 in SMAD4-null human PDAC cancer cells, reporting that inactivation of SMAD2/3 in SMAD4-negative PDAC cells compromised TGF-β-driven collective migration mediated by FAK and Rho/Rac signaling.